Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

Autor: G. von Minckwitz, S. Loibl, M. Untch, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, J. Huober, C. Solbach, C. Jackisch, G. Kunz, J.U. Blohmer, M. Hauschild, T. Fehm, V. Nekljudova, B. Gerber, K. Gnauert, B. Heinrich, T. Prätz, U. Groh, H. Tanzer, C. Villena, A. Tulusan, B. Liedtke, J.-U. Blohmer, C. Mau, J. Potenberg, J. Schilling, M. Just, E. Weiss, U. Bückner, M. Wolfgarten, R. Lorenz, G. Doering, S. Feidicker, P. Krabisch, U. Deichert, D. Augustin, K. Kast, C. Nestle-Krämling, C. Höß, J. Terhaag, P. Fasching, P. Staib, B. Aktas, T. Kühn, F. Khandan, V. Möbus, E. Stickeler, G. Heinrich, H. Wagner, A. Abdallah, T. Dewitz, G. Emons, A. Belau, V. Rethwisch, T. Lantzsch, C. Thomssen, U. Mattner, A. Nugent, V. Müller, T. Noesselt, F. Holms, T. Müller, J.-U. Deuker, D. Strumberg, C. Uleer, E. Solomayer, I. Runnebaum, H. Link, O. Tomé, H.-U. Ulmer, B. Conrad, G. Feisel-Schwickardi, C. Schumacher, T. Steinmetz, I. Bauerfeind, S. Kremers, D. Langanke, U. Kullmer, A. Ober, D. Fischer, A. Kohls, W. Weikel, J. Bischoff, K. Freese, M. Schmidt, W. Wiest, M. Sütterlin, M. Dietrich, M. Grießhammer, D.-M. Burgmann, B. Rack, C. Salat, D. Sattler, J. Tio, E. von Abel, B. Christensen, U. Burkamp, C.-H. Köhne, W. Meinerz, S.-T. Graßhoff, T. Decker, F. Overkamp, I. Thalmann, A. Sallmann, T. Beck, T. Reimer, G. Bartzke, M. Deryal, M. Weigel, P. Weder, C.-C. Steffens, S. Lemster, A. Stefek, F. Ruhland, M. Hofmann, J. Schuster, W. Simon, U. Kronawitter, M. Clemens, W. Janni, K. Latos, W. Bauer, A. Roßmann, L. Bauer, D. Lampe, V. Heyl, G. Hoffmann, F. Lorenz-Salehi, J. Hackmann, R. Schlag

Background The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane–based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd0d0889abbaa45ea11c291b5de85e20
https://www.ncbi.nlm.nih.gov/pubmed/25223482

Immunization with centrin -Deficient Leishmania braziliensis Does Not Protect against Homologous Challenge.

Autor: Avendaño-Rangel, Francys, Agra-Duarte, Gabriela, Borba, Pedro B., Moitinho, Valdomiro, Avila, Leslye T., da Silva, Larissa O., Viana, Sayonara M., Sharma, Rohit, Gannavaram, Sreenivas, Nakhasi, Hira L., de Oliveira, Camila I.

Publikováno v: Vaccines; Mar2024, Vol. 12 Issue 3, p310, 15p

Gene expression patterns associated with Leishmania panamensis infection in macrophages from BALB/c and C57BL/6 mice.

Autor: Restrepo, Carlos M.¹ (AUTHOR), Llanes, Alejandro¹ (AUTHOR), Herrera, Lizzi¹ (AUTHOR), Ellis, Esteban² (AUTHOR), Lleonart, Ricardo¹ (AUTHOR), Fernández, Patricia L.¹ (AUTHOR) pllanes@indicasat.org.pa

Publikováno v: PLoS Neglected Tropical Diseases. 2/22/2021, Vol. 15 Issue 2, p1-20. 20p.

CD11c-expressing Ly6C⁺CCR2⁺ monocytes constitute a reservoir for efficient Leishmania proliferation and cell-to-cell transmission.

Autor: Heyde, Sandrina¹, Philipsen, Lars¹, Formaglio, Pauline¹, Fu, Yan¹, Baars, Iris¹, Höbbel, Guido¹, Kleinholz, Corinna¹, Seiß, Elena A.¹, Stettin, Juliane¹, Gintschel, Patricia¹, Dudeck, Anne¹, Bousso, Philippe², Schraven, Burkhart^1,3, Müller, Andreas J.^1,4 andreas.mueller@med.ovgu.de

Publikováno v: PLoS Pathogens. 10/22/2018, Vol. 14 Issue 10, p1-30. 30p.

Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species.

Autor: dos Santos, Jéssica Cristina^1,2, Heinhuis, Bas¹, Gomes, Rodrigo Saar², Damen, Michelle S. M. A.¹, Real, Fernando³, Mortara, Renato A.³, Keating, Samuel T.¹, Dinarello, Charles A.^1,4, Joosten, Leo A. B.¹, Ribeiro-Dias, Fátima² fatimardias@gmail.com

Publikováno v: PLoS Neglected Tropical Diseases. 2/27/2017, Vol. 11 Issue 2, p1-21. 21p.